Adial Pharmaceuticals, Inc. has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on April 12, 2024, will not undergo review by the commission. The SEC's communication, dated April 17, 2024, was addressed to Cary Claiborne, the Chief Executive Officer of Adial Pharmaceuticals. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC has provided contact information for Lauren Hamill.

Adial Pharmaceuticals, Inc. has been informed by the United States Securities and Exchange Commission (SEC) that its registration statement on Form S-3, filed on April 12, 2024, will not undergo review by the commission. The SEC's communication, dated April 17, 2024, was addressed to Cary Claiborne, the Chief Executive Officer of Adial Pharmaceuticals. The SEC's letter also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. The SEC reminded the company and its management of their responsibility to ensure the accuracy and adequacy of their disclosures, regardless of the SEC's level of review or lack thereof. For further inquiries, the SEC has provided contact information for Lauren Hamill.